Ocrevus 300 mg concentrate for solution for infusion

  • DHPC
Company
Roche Registration GmbH
Active Ingredient
Dosage Form
Concentrate for solution for infusion
Legal Category
A - prescription, may not be renewed
Date of revision
10/2026

*Additional information is available within the SPC or upon request to the company

Direct Healthcare Professional Communications

  • Ocrevus (ocrelizumab) DHPC letter regarding the risk of drug-induced liver injury

    Direct Healthcare Professional Communication (DHPC)

    PDF515.94 KB

Roche Registration GmbH

3030 Lake Drive, Citywest Business Campus, Dublin 24, D24 KX6Y, Ireland

Email
ireland.druginfo@roche.com